Table 4

Association of genetic polymorphisms and pregnancy and oral contraceptive pill use with the risk of ovarian cancer

GenotypeCasesControlsORa95% CICasesControlsORa95% CIPb for interaction
Never pregnantEver pregnant
CYP1A1 (MspI)
m1/m19101c45660.80.3–2.4
 Any m21572.00.5–7.553611.10.4–3.10.56
CYP1A1 (Ile/Val)
A/A19101c71920.50.2–1.2
 Any G670.30.1–1.428350.50.2–1.30.18
CYP1A2
A/A1171c62600.90.3–2.7
 Any C1191.10.3–4.332620.50.2–1.60.39
CYP1B1
Leu/Leu11111c56841.00.4–2.8
 Any Val1463.81.0–14.647431.90.7–5.30.35
COMT
Val/Val1081c42600.90.3–2.6
 Any Met1591.80.5–6.858671.10.4–3.30.64
Never used oral contraceptive pillEver used oral contraceptive pill
CYP1A1 (MspI)
m1/m130231c24530.30.1–0.6
 Any m244231.60.7–3.524450.30.1–0.80.64
CYP1A1 (Ile/Val)
A/A53291c37730.20.1–0.4
 Any G23170.80.3–1.711250.20.1–0.50.77
CYP1A2
A/A46201c27470.20.1–0.4
 Any C22220.40.2–1.021490.10.1–0.30.23
CYP1B1
Leu/Leu46331c21620.20.1–0.4
 Any Val31131.80.8–4.030360.50.2–1.00.58
COMT
Val/Val36201c16480.20.1–0.4
 Any Met39260.90.4–2.034500.30.1–0.70.17
  • a Adjusted by multiple unconditional logistic regression for age, ethnicity, education, pregnancy history (in oral contraceptive pill models), oral contraceptive pill use (in pregnancy models), history of tubal ligation, and regularity of menstrual cycles.

  • b Based on the likelihood ratio test comparing models with and without an interaction term.

  • c Reference category.